PP01.01: Oncogenic Signaling is Rewired to Support Nucleotide Metabolism in Acquired Resistance to Targeted Therapies in NSCLC

PP01.03: Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC

PP01.05: Targeting MUC16-Mediated KRASi Resistance in NSCLC

PP01.06: Aurora Kinase A Inhibition Potentiates KRASG12C Inhibition and Overcomes Resistance to Sotorasib in Lung Cancer

PP01.07: Alterations in Tumor Suppressor Genes are Associated With Aggressive Disease Phenotypes in EGFR-Mutant NSCLC

PP01.08: Pilot Study to Evaluate the Potential of the Tumor-Educated Platelets (TEP) as the Tool to Detect Minimal Residual Disease and Drug Resistance

PP01.09: Integrin-Linked Kinase Drives Drug-Tolerant Persister Cell Survival and EMT in Response to EGFR Inhibition in Lung Adenocarcinoma

PP01.12: Extracellular Matrix Remodeling and Immune Evasion Drive Lung Adenocarcinoma Brain Metastasis

PP01.13: Temporal Immune Evolution in a Murine EML4-ALK NSCLC Model: Genomic, Proteomic, and Drug Co-Culture Characterization

PP01.14: Paired Sample Analyses of NSCLC After SCLC Transformation

PP01.15: Transcriptional Changes Associated with Tolerance to EGFR Tyrosine Kinase Inhibitors in Mutant EGFR Lung Cancer PDX Models

PP01.16: Ixazomib Overcomes Platinum Resistance and Induces Autophagy-Mediated Cell Death in Lung Adenocarcinoma

PP01.17: Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR) as Independent Prognostic Markers in EGFR- Tested Advanced Non-small Cell Lung Cancer

PP01.20: Predictive Utility of Circulating Tumor DNA in First- Line Osimertinib Therapy for EGFR-Mutant Metastatic Lung Adenocarcinoma

PP01.22: Targeting GTP-Bound KRAS and mTOR in Lung Adenocarcinoma and Squamous Cell Carcinoma Harboring KRAS G12C

PP01.25: Exploring the Impact of Socioeconomic and Geographic Factors on Immunotherapy Discontinuation and Success in Northern Ontario: A Retrospective, Single-Center Cohort Study

PP01.26: Investigating for Blood Circulating N-Linked Glycoproteins Associated With Immunotherapy Response in Pleural Mesothelioma